These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8121319)

  • 41. Effects of pentoxifylline and alprostadil on ocular hemodynamics in healthy humans.
    Dorner GT; Zawinka C; Resch H; Wolzt M; Schmetterer L; Garhofer G
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):815-9. PubMed ID: 17251482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
    Makis AC; Hatzimichael EC; Kolios G; Bourantas KL
    Haematologica; 2004 Mar; 89(3):360-1. PubMed ID: 15020278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The effects of terazosin hydrochloride and buflomedil in patients with hemicrania without aura].
    Paterna S; Martino S; Ingurgio NC; Arrostuto A; Correo S; Licata G
    Clin Ter; 1994 Apr; 144(4):307-19. PubMed ID: 7911406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of buflomedil on behaviour, memory, and intellectual capacity in patients with dementia. A placebo-controlled study.
    Levinson B; Wright P; Barklem S
    S Afr Med J; 1985 Aug; 68(5):302-7. PubMed ID: 3898413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A review of long-term safety data with buflomedil.
    Bachand RT; Dubourg AY
    J Int Med Res; 1990; 18(3):245-52. PubMed ID: 2193838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Inhibition of histamine-induced wheal, flare and doppler laser flowmetry during long-term (180 days) of cetirizine 10 mg per day treatment].
    Kruszewski J; Kłos K; Sułek K
    Pol Merkur Lekarski; 2005 Dec; 19(114):758-60. PubMed ID: 16521417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of vazaprostan on microcirculation in patients with scleroderma systematic].
    Alekperov RT; Mach ES; Guseva NG
    Ter Arkh; 2000; 72(10):60-4. PubMed ID: 11220881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up.
    Le Quentrec P; Lefebvre ML
    Angiology; 1991 Apr; 42(4):289-95. PubMed ID: 1673051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Doppler flowmeter evaluation of the effects of the administration of buflomedil (irrodan) on peripheral circulation in patients with obstructive chronic arteriopathy].
    Abate S; Ferulano GP; Vanni L; Dilillo S; Picilli M; D'Alessio E
    Minerva Cardioangiol; 1985 Nov; 33(11):749-56. PubMed ID: 2935748
    [No Abstract]   [Full Text] [Related]  

  • 51. A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study.
    Gonzalez P; Hackney AC; Jones S; Strayhorn D; Hoffman EB; Hughes G; Jacobs EE; Orringer EP
    J Investig Med; 1997 Jun; 45(5):258-64. PubMed ID: 9249998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blood pressure in acute vaso-occlusive crises of sickle cell disease.
    Ernst AA; Weiss SJ; Johnson WD; Takakuwa KM
    South Med J; 2000 Jun; 93(6):590-2. PubMed ID: 10881775
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of buflomedil in reduction mammaplasty for a previously irradiated breast: a case report.
    Sterodimas A; Vargas A; Radwanski HN; Pitanguy I
    Aesthetic Plast Surg; 2008 Mar; 32(2):383-5. PubMed ID: 18058164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nimodipine plasma concentration and retinal blood flow in healthy subjects.
    Michelson G; Wärntges S; Leidig S; Lötsch J; Geisslinger G
    Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3479-86. PubMed ID: 16877419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants.
    Amer J; Ghoti H; Rachmilewitz E; Koren A; Levin C; Fibach E
    Br J Haematol; 2006 Jan; 132(1):108-13. PubMed ID: 16371026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients.
    Bao B; Prasad AS; Beck FW; Snell D; Suneja A; Sarkar FH; Doshi N; Fitzgerald JT; Swerdlow P
    Transl Res; 2008 Aug; 152(2):67-80. PubMed ID: 18674741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?].
    Mariéthoz S; Pittet B; Loutan L; Humbert J; Montandon D
    Ann Chir Plast Esthet; 1999 Feb; 44(1):81-8. PubMed ID: 10188298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of hydroxyurea on hemoglobin S].
    Torres AF; Eberle SE; Sciuccati G; Bonduel M
    Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral buflomedil in diabetic background retinopathy: results of a preliminary controlled study.
    Ducrey N; Curchod B
    J Int Med Res; 1984; 12(3):184-7. PubMed ID: 6734921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An experimental overview of a new vasoactive drug: buflomedil HCl.
    Dubourg A; Scamuffa RF
    Angiology; 1981 Oct; 32(10):663-75. PubMed ID: 7034590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.